Gene-based Therapy Subject Matter Expert Support
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $700,000 to $1,500,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health plans to award 1–2 Total Small Business contracts for gene-based therapy subject matter expert support under NAICS 541990, replacing current contracts that end in October 2026, with an estimated solicitation release of 2026-03-01 and an estimated award date of 2026-08-01. The contracts focus on oligonucleotide and gene therapy expertise, which represents over half of projects across the HEAL, Ultra-rare Gene-based Therapy, and Blueprint for Neurotherapeutics programs that support 14 Institutes and Centers, with gene therapy projects at NINDS as the stated focus. Required expertise spans biologics development (chemistry, manufacturing, toxicology, pharmacology, and regulatory support) on a non-full-time basis, which NIH states is not available internally.
The estimated award value range is $700,000 to $1.5 million, and the $30,000 initial award covers a base of 20 hours and 80 optional hours to address current known needs. The source does not state a place of performance. Points of contact are Kelly Sheppard (kelly.sheppard@nih.gov) and Michael Falzone, Contracting Officer, Legal - Contracts (michael.falzone@nih.gov, +13018271873), both at the National Institutes of Health.
Forecast text
Continued subject matter expertise is necessary to support Helping End Addiction Long-term (HEAL), Ultra-rare Gene-based Therapy, and Blueprint for Neurotherapeutics therapy development programs. These programs support 14 Institutes and Centers and require broad expertise in all areas of biologics development (chemistry, manufacturing, toxicology, pharmacology, and regulatory support). This request is to issue new contracts to supply needed expertise as the current contracts end in October 2026. The request is for 1-2 contracts to be awarded focused on gene-based therapy expertise supporting gene therapy projects at NINDS. The $30k amount in this order is the initial award, which we anticipate being the base 20 hours and 80 optional hours to support known needs right now. The contracts will focus on oligonucleotide and gene therapy expertise, which represents over half of projects coming through these programs. This type of expertise is not available internally at NIH and is not needed on a full-time basis. Not having this support increases the likelihood of projects failing due to lack of expert guidance and lost investment in these efforts.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast